Neoantigens are peptides on the surface of cancer cells that may activate the immune system. Multiple novel therapeutic approaches involve identifying and predicting which neoantigens can be leveraged to trigger immunity-induced tumor regression. Accurate, reproducible, and rapid discovery of neoantigen candidates represents a foundation for personalized cancer vaccine development. Paired with a cloud environment, this neoantigen workflow has the potential to fulfill the demands for rapid turn-around of accurate predictions within a clinically compliant environment for a large number of patients.
Key points you will learn: